Seminars in Oncology Nursing
Volume 25, Issue 2 , Pages 129-138 , May 2009

Acute Complications of Stem Cell Transplant

  • Chris Rimkus

      Affiliations

    • Corresponding Author InformationAddress correspondence to Chris Rimkus RN, MSN, AOCN®, Clinical Nurse Specialist, Blood and Marrow Transplant Program, 216 S. Kingshighway, Barnes-Jewish Hospital, Siteman Cancer Center, St. Louis, MO 63110

References 

  1. Center for International Blood & Marrow Transplant Research. Progress Report January – December 2007. Available at: http://www.cibmtr.org/ABOUT/Annual_Report/DOCS/annual_report.pdf. (accessed Nov 6, 2008.).
  2. Artz AS, Pollyea DA, Kocherginsky M, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12:954–964
  3. Sorror MI, Maris MB, Storb R, et al. Hematopoietic cell transplant (HCT)-specific comorbidity index. Blood. 2005;106:2912–2918
  4. Niess D, Duffy KM. Basic concepts of transplant. In Ezzone S, ed. Hematopoietic stem cell transplant: a manual for nursing practice. Pittsburgh, PA: Oncology Nursing Society; pp 13-21.
  5. Morandi P, Ruffinin PA, Benvenuto GM, et al. Cardiac toxicity of high dose chemotherapy. Bone Marrow Transplant. 2005;35:323–334
  6. Tiersten A, Wo J, Jacobson C, et al. Cardiac toxicity observed in association with high dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast. 2004;13:341–346
  7. Fadol A. Management of acute decompensated heart failure in patients with cancer. Clin J Oncol Nurs. 2006;10:731–736
  8. Cavet J, Lennard A, Gascoigne A, et al. Constrictive pericarditis post allogeneic bone marrow transplant for Philadelphia-positive acute lymphocytic leukemia. Bone Marrow Transplant. 2000;25:571–573
  9. Snowdenm JA, Hill GR, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant. 2000;26:309–313
  10. Fischer VL, Barnes YJ, Nuss SL. Pretransplant conditioning in adults and children: dose assurance with busulfan. Oncol Nurs Forum. 2006;33:E36–E43
  11. Horn TD, Beveridge RA, Egorin MJ, et al. Observations and proposed mechanisms of N2N'N”-triethylene-thiophosphoramid (thiotepa)-induced hyperpigmentation. Arch Dermatol. 1989;125:524–527
  12. Rosman HS, Lloyd BM, Hayashi RJ, et al. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplant. J Am Acad Dermatol. 2008;58:575–578
  13. Kerbusch T, de Kraker J, Keizer HJ. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Bone Marrow Transplant. 2001;40:41–62
  14. Patel PN. Methylene blue for the treatment of ifosphamide-induced encephalopathy. Ann Pharmacother. 2006;40:299–303
  15. Junglee D, Katrak A, Mohiuddin J, et al. Salivary amylase and pancreatic enzymes in serum after total body irradiation. Clin Chemistry. 1986;32:609–610
  16. McAdams W, Burgunder R. Transplant course. In:  Ezzone S editors. Hematopoietic stem cell transplantation: a manual for nursing practice. Pittsburgh, PA: Oncology Nursing Society; 2005;p. 43–59
  17. Parikh CR, Sandmaier BM, Storb RF, et al. Acute renal failure after nonmyeloablative hematopoietic cell transplant. J Am Soc Nephrol. 2004;15:1868–1876
  18. Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with caner and its treatment: an update. J Am Soc Nephrol. 2005;16:151–161
  19. Higman MA, Port JD, Beauchamp NJ, et al. Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stem cells. Bone Marrow Transplant. 2000;26:797–800
  20. Hequet O, Dumontet AEI, Jaafari-Corbin G, et al. Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. Bone Marrow Transplant. 2002;29:544
  21. Lilleby K, Garcia B, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplant. Bone Marrow Transplant. 2006;37:1031–1035
  22. Papus AS, Clark RE, Martuscelli G, et al. A prospective randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplant. Bone Marrow Transplant. 2003;31:705–712
  23. Lagner S, Stager P, Schub N, et al. Palifermin reduces the incidence and severity of oral mucositis in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2008;42:275–279
  24. Loerzel VW, Dow KH. Cardiac toxicity related to cancer treatment. Clin J Oncol Nurs. 2003;7:557–562
  25. Crawford SW. Critical care and respiratory failure. In:  Thomas ED,  Blume KG,  Forman SJ editor. Hematopoietic cell transplantation. Boston, MA: Blackwell Science; 1999;p. 712–722
  26. Keller CA. Cardiopulmonary effects. In:  Ezzone S editors. Hematopoietic stem cell transplantation: a manual for nursing practice. Pittsburgh, PA: Oncology Nursing Society; 2005;p. 177–189
  27. Wanko SO, Broadwater G, Folz RJ, et al. Diffuse alveolar hemorrhage: retrospective review of clinical outcomes in allogeneic transplant recipients treated with aminocaproic acid. Biol Blood Marrow Transplant. 2006;12:949–953
  28. Latchford T, Shelton BK. Respiratory syncytial virus in blood and marrow transplant recipients. Clin J Oncol Nurs. 2003;7:418–422
  29. Avery R, Kalaycio M, Pohlman B. Early vancomycin enterococcus bacteremia (VRE) bacteremia after allogeneic stem cell transplant is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant. 2005;35:497–499
  30. Tomblyn M, Gordon L, Singhal S, et al. Rarity of toxigenic clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant. 2002;30:517–519
  31. Gorschluter M, Mey U, Strehl J, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence of quality. Eur J Haematol. 2005;75:1–13
  32. Gobel BH, Peterson GJ. Sepsis and septic shock. In:  Kaplan M editors. Understanding and managing oncologic emergencies: a resource for nurses. Pittsburgh, PA: Oncology Nursing Society; 2006;p. 159–195
  33. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstructive syndrome (veno-occlusive disease). Semin Liver Dis. 2002;2:27–42
  34. Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther. 2006;23:11–25
  35. Akasheh M, Eastwood D, Vesole DH. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte colony stimulating factor (GCSF) versus granulocyte-macrophage colony stimulating factor (GMCSF). Bone Marrow Transplant. 2003;31:113–116
  36. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893–898
  37. Barton-Burke M, Dwinell DM, Kafkas L, et al. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant. Oncology. 2008;22(suppl 11):31–40
  38. Machado M, Moreb J, Khan SA. Five cases of permanent alopecia after various conditioning regimens commonly used in bone marrow transplant. Biol Blood Marrow Transplant. 2007;13:50–51
  39. Chegounchi M, Hanna MG, Neild GH. Progressive neurologic disease induced by tacrolimus in a renal transplant recipient: a case presentation. BMC Nephrol (online). Available at: http://www.biomedcentral.com/1471-2369/7/7. (accessed Oct 8, 2008).
  40. Sigeal D, Keller A, Xu W. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant. 2007;13:1369–1379
  41. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571–575
  42. Visser AM, van Doornum GJJ, Cornelissen JJ, et al. Severe amnesia due to HHV-6 encephalitis after allogeneic stem cell transplantation. Eur Neurol. 2005;54:233–234
  43. Hentich M, Oruzio D, Jager G, et al. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol. 2004;128:66–72
  44. Jones RB, Mathes S, Shpall BJ, et al. Acute lung injury following treatment after high-dose cyclophosphamide, cisplatin, carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst. 1993;85:640–647
  45. Akasheh MS, Frytes CO, Vesole DH. Melphalan-associated lung toxicity following high-dose chemotherapy with hematopoietic stem cell transplant. Bone Marrow Transplant. 2000;26:1107–1109
  46. Shen YC, Chiu CF, Chow KC, et al. Fatal fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor-I, transforming growth factor-b1, and cyclooxygenase-2. Bone Marrow Transplant. 2004;34:609–614
  47. Federoff A. BK virus in hematopoietic stem cell transplantation recipients. Clin J Oncol Nurs. 2008;12:895–900

PII: S0749-2081(09)00026-6

doi: 10.1016/j.soncn.2009.03.007

Seminars in Oncology Nursing
Volume 25, Issue 2 , Pages 129-138 , May 2009

Article Tools